Comparative Pharmacology
Head-to-head clinical analysis: LAMICTAL ODT versus VIGABATRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMICTAL ODT versus VIGABATRIN.
LAMICTAL ODT vs VIGABATRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamotrigine is a triazine derivate that stabilizes presynaptic neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting the release of excitatory neurotransmitters (e.g., glutamate). This suppresses neuronal hyperexcitability and prevents seizure spread.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg daily every 1-2 weeks; maintenance 100-200 mg twice daily (200-400 mg/day). For monotherapy or as add-on in epilepsy and bipolar disorder.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
None Documented
None Documented
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
Terminal elimination half-life: 25-39 hours (single dose), 12-22 hours (with enzyme inducers), 30-70 hours (with valproate); clinically relevant for dosing titration to avoid Stevens-Johnson syndrome
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Primarily hepatic metabolism (glucuronidation by UGT1A4); 70-90% excreted renally as metabolites, 2% unchanged; 2-10% fecal
Renal: ~80% unchanged in urine; fecal: <5%.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."